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Abstract
Background: Head and neck cancer patients undergoing concomitant chemoradiotherapy (CCRT) frequently
experience loss of muscle mass and reduced functional performance. Positive effects of exercise training are
reported for many cancer types but biological mechanisms need further elucidation. This randomized study
investigates whether progressive resistance training (PRT) may attenuate loss of muscle mass and functional
performance. Furthermore, biochemical markers and muscle biopsies will be investigated trying to link biological
mechanisms to training effects.
Methods: At the Departments of Oncology at Herlev and Aarhus University Hospitals, patients with stage III/IV squamous
cell carcinoma of the head and neck, scheduled for CCRT are randomized 1:1 to either a 12-week PRT program or control
group, both with 1 year follow-up. Planned enrollment is 72 patients, and stratification variables are study site, sex, p16-
status, and body mass index. Primary endpoint is difference in change in lean body mass (LBM) after 12 weeks of PRT,
assessed by dual-energy X-ray absorptiometry (DXA). The hypothesis is that 12 weeks of PRT can attenuate the loss of
LBM by at least 25%. Secondary endpoints include training adherence, changes in body composition, muscle strength,
functional performance, weight, adverse events, dietary intake, self-reported physical activity, quality of life, labor market
affiliation, blood biochemistry, plasma cytokine concentrations, NK-cell frequency in blood, sarcomeric protein content in
muscles, as well as muscle fiber type and fiber size in muscle biopsies. Muscle biopsies are optional.
Discussion: This randomized study investigates the impact of a 12-week progressive resistance training program on lean
body mass and several other physiological endpoints, as well as impact on adverse events and quality of life.
Furthermore, a translational approach is integrated with extensive biological sampling and exploration into
cytokines and mechanisms involved. The current paper discusses decisions and methods behind exercise in
head and neck cancer patients undergoing concomitant chemoradiotherapy.
Trial registration: Approved by the Regional Ethics Committee for the Capital Region of Denmark (protocol
id: H-15003725) and registered retrospectively at ClinicalTrials.gov (NCT02557529) September 11th 2015.
Keywords: Head and neck cancer, Head and neck squamous cell carcinoma, Chemoradiotherapy, Progressive
resistance training, Exercise, Physical activity, Body composition, Lean body mass, Body weight, Weight
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Background
Patients with locally advanced head and neck squamous
cell carcinoma (HNSCC) undergoing concomitant chemo-
radiotherapy (CCRT) are often subjected to severe treat-
ment side effects which may lead to weight loss, including
loss of lean body mass, negatively impacting physical func-
tion and maybe even treatment outcome [1–7]. The loss
of lean body mass (LBM) during treatment is likely to be
multifactorial and HNSCC patients are particularly sus-
ceptible for several reasons: Cancer disease per se can
cause muscle wasting [8, 9]; along with cisplatin chemo-
therapy [10, 11] and prednisolone [12, 13], which is often
used as antiemetic treatment. Furthermore, many HNSCC
patients fail to maintain sufficient energy and protein
intake for a period of time [14, 15] due to treatment side
effects, e.g. mucositis, dry mouth, pain, and fatigue. This
may render patients in a catabolic state, a condition that
inevitably will lead to further loss of muscle mass [16] as
muscles are the largest and primary protein and energy
reserve of the body. Interestingly, it has been shown that
patients fail to maintain weight and LBM despite sufficient
dietary intake [14], hence other interventions with poten-
tial to attenuate muscle wasting in HNSCC patients dur-
ing treatment are needed.
In a preclinical study voluntary exercise efficiently miti-
gated cisplatin-induced muscle wasting [17]. Specifically,
progressive resistance training (PRT) induces muscle
hypertrophy in both healthy adults and cancer patients
and definitely holds the potential to counteract cancer-
related muscle wasting, too [8, 18, 19]. Twelve weeks of
PRT after radiotherapy has been shown to rebuild LBM in
HNSCC patients [20, 21], hence, PRT could be a meaning-
ful approach for LBM preservation during treatment.
In a pilot study of a 12-week supervised PRT program
during CCRT at our facility, we found that the interven-
tion was feasible and appreciated by patients (Lonkvist et
al., manuscript submitted). Knowing this, the present ran-
domized trial is launched to investigate whether PRT dur-
ing CCRT has a clinically relevant advantage, in terms of
attenuated loss of LBM, compared with a control group
not offered any structured training. In addition, extensive
biological sampling is incorporated in this study adopting
a translational approach, with the aim of exploring not
only if it works, but also contributing to questions of how
and why.
There is an echoing lack in clinical studies investigating
the biological mechanisms. Preclinical studies demon-
strate a direct inhibitory effect on cancer growth through
different mechanisms [22–26]. One very plausible mech-
anism being exercise-mediated induction of intratumoral
natural killer cells (NK cells) [27], unequivocally linking
exercise to attenuation of tumor growth in mice [28, 29].
Exercise in its broadest sense is a very heterogeneous
activity making the description of exercise interventions
in clinical trials critical [30]. This article describes the
study design of a 12-week progressive resistance training
program in head and neck cancer patients undergoing
concomitant chemoradiotherapy, sharing thoughts be-
hind the decision making.
Methods/design
Design
In this prospective phase II multi-center randomized
study in patients with HNSCC scheduled for radiother-
apy concomitant with chemotherapy (cisplatin), the ef-
fects of 12-week PRT are investigated. The study is
planned to include 72 patients from the departments of
oncology at Aarhus and Herlev Hospitals in Denmark,
see study flow in Fig. 1. Also, a third center was opted to
participate but this site will not be including patients
due to capacity issues.
Ethics approval has been obtained from the regional
Ethics Committee for the Capital Region of Denmark
(H-15003725) and the Danish Data Protection Agency
(HGH-2015-003; 2005–41-4802; 2014–41-3510). The
study is registered at clinicaltrials.gov (NCT02557529)
September 11th 2015. This article describes protocol
version 4.0 from April 1st 2016.
The manuscript applies to the SPIRIT guidelines of ran-
domized trials. The SPIRIT checklist, appendix for the
SPIRIT checklist, as well as the World Health Organization
(WHO) Trial Registration Data Set can be found in
additional files 1, 2 and 3.
Fig. 1 Overall study design
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Participants
Patients are eligible if the following inclusion criteria are
fulfilled: 1) Histologically verified primary head and neck
squamous cell carcinoma (HNSCC) of the oral cavity,
oropharynx, hypopharynx, larynx, or in lymph nodes of
the neck from an unknown primary tumor; 2) candidate
for curatively intended CCRT (weekly cisplatin during
radiotherapy, 66–68 Gy) according to Danish Head and
Neck Cancer (DAHANCA) group (i.e. patients with
stage III-IV disease, www.dahanca.dk) [31]; 3) perform-
ance status (PS) 0–1 (Eastern Cooperative Oncology
Group Performance (ECOG); 4) age ≥ 18 years; 5) signed
informed consent.
Exclusion criteria are: 1) Body Mass Index (BMI) < 20.5;
2) comorbidity potentially interfering with attendance or
test results, e.g. other cancers, diabetes, prednisolone treat-
ment); 3) tonsillectomy within 1 week before inclusion; 4)
psychological, social or geographical conditions that could
influence protocol adherence; 5) insufficient bone marrow
function (hemoglobin <6 mmol/L, leucocytes <2.5 × 109/L,
or thrombocytes <50 × 109/L; 6) diastolic blood pres-
sure < 45 or >95, resting heart rate > 100; 7) signs of ische-
mia on electrocardiogram; 8) pregnancy.
Randomization
Patients will be stratified by site (Herlev/Aarhus), sex
(male/female), p16-status of the tumor (positive/nega-
tive) and BMI (<30/≥30) and randomized 1:1 to either a
training group performing a 12-week PRT program or
control group. If a patient leaves the study within the
first week, the number of patients randomized will be
increased by one. Patient inclusion form is faxed to The
Danish Head and Neck Cancer (DAHANCA, Aarhus,
Denmark) group administration, that performs the
randomization using a software randomization file (de-
veloped and used by the DAHANCA group) that auto-
matically and randomly allocates each patient in either
group. The personnel conducting the randomization are
independent of clinical personnel and are not otherwise
involved in the study.
Treatment
All patients will receive curatively intended CCRT, 66 to
68 Gy, in 2 Gy fractions, 6 fractions/week, with concur-
rent nimorazole perorally (1200 mg/m2) [32] before each
fraction (1000 mg/m2 for same day second fraction), and
weekly cisplatin (40 mg/m2, max. 70 mg). Prophylactic
antiemetics are administered according to institutional
guidelines (Additional file 4: Table S1).
Intervention
The PRT program comprises seven conventional resist-
ance training exercises targeting the large muscle groups
of the body (chest press, low row (Herlev site)/lateral
pull down (Aarhus site), hamstring curls, knee extension,
leg press, abdominal crunches (Herlev site)/sit ups (Aar-
hus site), back extensions) (Additional file 5: Figure S1).
The latter two included primarily to ensure a full body
workout. The training protocol (Table 1) was tested in
our pilot study (Lonkvist et al., manuscript submitted)
and is almost identical to the protocol developed and
used in the DAHANCA 25 trials [20, 21]. The first week
is an introductory week with high repetition number
and low load, as many HNSCC patients are resistance
training naïve. The intensity and volume progressed
throughout the program from two to three sets with a
load corresponding to 15 to 8 repetition maximum
(RM), i.e. the load that can be lifted respectively 15 to 8
times using proper technique (See Tables 1 and 2). This
progression model is in accordance with the guidelines
from the American College of Sports Medicine (ACSM)
[33]. Due to the focus on muscular hypertrophy, patients
are urged to perform all sets in all exercises to exhaus-
tion within the given RM target, thereby ensuring local
muscular fatigue. In accordance, patients are instructed
to perform all sets of each exercise before moving on to
the next exercise and also to perform the lower body
exercises after each other before moving to upper body
exercises. Each exercise is executed in full range of mo-
tion and with rest periods of no more than 60 s between
sets (Table 2). If more repetitions than planned can be
performed, the training load will be increased to match
the specific RM target. Training sessions are planned
three times a week every other day ensuring optimal re-
covery time for maximal hypertrophic response. In case
of temporary discontinuation, patients will proceed with
the same weight as when they paused, but will be ad-
justed to ensure the proper RM target is reached.
The PRT program starts concurrently with CCRT. 36
training sessions are planned, i.e. thrice weekly for 12 weeks,
thus continuing approximately 6 weeks further than CCRT.
If a session is cancelled due to treatment related interven-
tions, radiotherapy, scans, or due to public holidays, the
session will be replaced at the end of the training program.
Sessions missed for personal reasons or incapacitation will
not be substituted. It will be ensured that the PRT program
and tests never compromise treatment schedule.
At the Herlev site conventional exercise equipment is
used for all exercises but due to different equipment
Table 1 Exercise progression model
Training session Repetitions Sets
1–3 15 2
4–6 12 2
7–18 12 3
19–31 10 3
32–36 8 3
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available at the involved sites, three specific exercises
differ but with only minimal difference in target muscle
groups or progression options. Thus, at the Aarhus site
sit-ups will be performed as traditional floor exercises
with free weights ensuring possible progression in inten-
sity. Hamstring curls will be performed using elastic
bands (TheraBand, The Hygenic Corporation, Ohio,
USA) with varying resistance and lateral pull down re-
places low seated row in Aarhus. Conventional resist-
ance training machines (Technogym, Gambettola, Italy)
are used at both sites.
During the first 6 weeks all training sessions are super-
vised by physiotherapist or educated training instructors.
When possible the same supervised training modality at
the hospital training facility will continue for the remaining
6 weeks. If a patient is unable to attend training sessions at
the hospital, e.g. due to prolonged transport time, the
remaining training sessions will be tailored individually at
commercial training facilities near the patients’ own home.
However, patients must attend at least one session per
week supervised at the hospital training facility.
If patients, due to treatment side effects, are unable to
attend at least one weekly training session, they will be
given a leaflet describing two simple exercises (backward
lunges and push-ups), and they will be encouraged to do
the exercises (3 sets, 12 repetitions) every day until they
are able to attend the supervised training again. Patients
will fill in training logs during every session from which
training adherence, changes in training volume, and in-
tensity are reported.
No direct criteria for discontinuing the training pro-
gram are provided, but if a patient feels incapable of
training or if the physician, physiotherapist or training
instructor deems the patient’s general condition not
compatible with training, the program will be paused.
To support energy intake and mitigate negative energy
balance on training days, patients are offered a meal
and/or a protein supplement (e.g. Nutridrink compact
(Nutricia), 125 mL, 1260 kJ, 12 g protein) immediately
after training sessions. Patients in both groups are con-
tinuously screened (i.e. body weight assessments) by
trained nurses ensuring the best possible energy intake to
limit the risk of catabolic state during the CCRT and the
approximately 6-week follow-up period immediately after.
Controls
No restrictions on physical activity (PA) or other con-
comitant care are made for the control patients but no
organized training will be offered to them. PA is re-
ported in training logs. Except for blood sampling which,
obviously, will not be drawn after any training session
(see below) in the control group, there are no differences
in tests and assessments between the groups.
Study objectives and assessments
The primary endpoint is change in lean body mass (LBM).
Secondary endpoints are training adherence and changes
in and difference between groups in body composition,
muscle strength, functional performance, weight, adverse
events, dietary intake, self-reported PA, quality of life
(QoL), labor market affiliation, blood biochemistry, cyto-
kines in plasma, NK-cells in peripheral blood, sarcomeric
protein content in muscles, as well as muscle fiber type
and fiber size in muscle biopsies. See Table 3 for all assess-
ment time points.
Clinical outcomes
Body composition
The primary endpoint is change in lean body mass (LBM)
which will be assessed after 12 weeks of PRT or control
using Dual Energy X-ray Absorptiometry (DXA) (Herlev
site: GE lunar iDXA, GE Healthcare Technologies; Aarhus
site: Hologic QDR-series, Hologic Inc., Bedford, MA,
USA). The hypothesis is that 12 weeks of progressive
resistance training can attenuate the loss of LBM by at
least 25%. This time span was chosen since 12 weeks are
considered a sufficient period of PRT needed to affect
LBM. Furthermore, this time point is a usual evaluating
point for head and neck cancer as it coincide with the 2-
month post-radiotherapy follow-up. Changes in total body
mass and fat mass will also be assessed. Total body weight,
with patients in light clothing and no shoes, will be mea-
sured weekly by the same digital scale at each site during
therapy and bi-weekly thereafter.
Adherence
Adherence to the PRT program is registered by the
physiotherapist or educated training instructors. Adher-
ence to the study in general is encouraged by highlighting
the importance of both groups in order for the trial to
produce valid results. Furthermore, most appointments
are planned when patients already have an appointment at
Table 2 Description of the PRT program
Load 15 RM (week 1), 12 RM (week 2–6),
10 RM (week 7–10), 8 RM (week 11–12)
Repetitions 15 (week 1), 12 (week 2–6), 10
(week 7–10), 8 (week 11–12)
Sets per sessions 2 (week 1–2), 3 (week 3–12)
Sessions per week 3
Duration of training period 12 weeks
Rest between sets 45–60 s
Rest between repetitions 0 s
Range of motion Maximum possible
Rest between training sessions Training every other day
Abbreviations: PRT progressive resistance training, RM repetition maximum,
e.g. 15 RM is the heaviest load that can be lifted 15 times using proper
technique. Sec, seconds
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the hospital, making it as convenient as possible for the
patients.
Maximal muscle strength
All physical tests are conducted by the physiotherapist
or the training instructors. Muscle strength will be eval-
uated by 1RM test of unilateral leg press (dominant leg)
and bi-lateral chest press performed in the conventional
equipment used in training. One RM tests are widely
used when evaluating changes in maximal muscle
strength in cancer patients [34, 35]. Following an exer-
cise specific warm up, the patient will have one attempt
with a given load, which will gradually be increased
until the patient is unable to lift the load throughout a
standardized range of motion using proper technique.
As few attempts as possible will be used and a two-
minute rest is ensured between all attempts to limit the
risk of muscular fatigue.
Functional performance
Functional performance resembling activities of daily liv-
ing will be evaluated using the 30 s chair stand test, 30 s
arm curl test, and maximal stair climbing performance,
best of two attempts. These are frequently used in can-
cer patients, including patients with HNSCC [20].
Treatment side-effects
Adverse events will be monitored according to Common
Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.0 [36], performance status will be registered ac-
cording to ECOG scale, and pain using the Numeric
Rating Scale (NRS) for pain, consisting of 11 points from
0 (no pain) to 10 (worst pain imaginable) [37].
Cytokine analyses, standard blood samples, and NK-cells
Standard blood samples will be taken according to
schedule (Table 3). Blood samples for cytokine analyses
Table 3 Time schedule for study assessments
X marks when an examination is planned. XX marks at which time points blood samples are drawn both before and after a training session in the training group.
Regarding week 13/14: Due to public holidays training can extend beyond 12 weeks, training continues until 36 sessions have been offered. Blood samples are
drawn, weight registered and other examinations are performed after the 36 sessions. Abbreviations: ALT, alanine aminotransferase. ALP, alkaline phosphatase.
e-GFR, estimated glomerular filtration rate. LDH, lactate dehydrogenase. HS-CRP, high-sensitive c-reactive protein. TSH, thyroid stimulating hormone. INR,
international normalized ratio. DXA, dual-energy X-ray absorptiometry. Approx., approximately
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will be taken before and after training sessions according
to schedule (Table 3). Based on comprehensive explorative
analyses with samples from a primary cohort of patients
(Lonkvist et al., manuscript submitted), we have identified
a list of particularly interesting cytokines and other mole-
cules for further analyses, including 6Ckine/chemokine
(C-C motif) ligand 21 (CCL21), cutaneous T cell-attracting
chemokine (CTACK)/CCL27, interleukin 6 (IL-6), IL-8/
CXCL8, IL-15, IL-16, monocyte chemoattractant protein 1
(MCP-1)/CCL2, MCP-2/CCL8, macrophage-derived che-
mokine (MDC)/CCL22, macrophage migration inhibitory
factor (MIF), macrophage inflammatory protein-1α (MIP-
1α)//CCL3, thymus-expressed chemokine (TECK)/CCL25,
tumor necrosis factor α (TNF-α), soluble epidermal growth
factor receptor (sEGFR), basic fibroblast growth factor
(FGF-basic), follistatin, hepatocyte growth factor (HGF),
leptin, platelet-derived growth factor AB/BB (PDGF-AB/
BB), prolactin, stem cell factor (SCF), soluble vascular
endothelial growth factor-1 (sVEGFR-1), and sVEGFR-2. In
initial analyses some of these cytokines increased during
CCRT whilst others decreased, and the interesting point
would be to investigate if PRT may affect these changes in
either direction. Furthermore, the mobilization of
NK-cells during PRT will be evaluated in week 3 and
12. The frequency and cytotoxic profile of the NK-
cells will be analyzed by flow cytometry by staining
for the surface receptors CD3, CD16 and CD56, as
well as intracellular expression of Granzyme B and
Ki-67.
Muscle biopsies
Muscle biopsies are optional for patients, but if ac-
cepted, they will be collected under sterile conditions
from the middle lateral part of the vastus lateralis
muscle using a 5 mm Bergstrom biopsy cannula preceded
by local anesthesia (lidocaine 10 mg/ml). Both satisfactory
thrombocyte count (≥ 40 × 109/L) and International
Standard Ratio (≤ 1.5) will be confirmed. Biopsies are
taken from the mid-thigh of the same leg but a few centi-
meters from the previous biopsy at each time point to
avoid variation between legs in the analyses. The sam-
ples will be dissected to be free of visible fat and con-
nective tissue. A well-aligned portion of the biopsy for
muscle fiber morphology analyses will immediately
mounted in Tissue-Tek (Qiagen, Valencia, CA) and fro-
zen in isopentane precooled in liquid nitrogen. The rest
of the biopsy for later proteomics analyses will be fro-
zen directly in liquid nitrogen. All samples will be
stored at −80 °C until analysis.
The muscle biopsies are planned to be used for inves-
tigating differences in changes in muscle fiber types,
protein expression, and metabolic pathways between the
two groups.
Questionnaires
Physical activity
To register PA in addition to the supervised training of
the PRT group as well as all PA in the control group, pa-
tients will fill in a weekly trial specific questionnaire on
PA. Thus, type of activity (running, resistance training,
walking etc.) and the daily duration of the activity will
be registered every week from baseline to the end of the
training period. Also, patients will fill in a physical activ-
ity scale (PAS) questionnaire for measuring average
weekly PA of sleep, work, and leisure time [38].
Energy intake
Patients will receive dietary counseling by clinical diet-
ician before or immediately after start of treatment as
well as by educated nurses during the treatment period.
If patients are admitted due to nutritional issues during
the treatment period, they will be seen by a clinical diet-
ician. Resting metabolic rate (RMR) will be estimated
using the Mifflin-St. Jeor formula described elsewhere
[39]. Energy expenditure (kilojoules per day) is measured
as: Energy need (kJ) = RMR x activity factor × 4.184.
Activity factor will be based on self-reported PA at the
different time points. Protein need will be estimated as
18% of total energy need: Protein need (gram) = (total
energy need (kJ) × 18)/17. A clinical dietician will calcu-
late total daily energy intake based on patient reported
information from a questionnaire filled in weekly during
treatment (Table 3). The number of patients needing
tube feeding and the duration of the tube feeding will
also be registered.
Quality of Life (QoL)
Changes in QoL will be evaluated using the European Or-
ganisation for Research and Treatment of Cancer (EORTC)
quality of life questionnaires, QLQ-C30 and QLQ-H&N-
35, which have previously been used in exercise studies in
cancer survivors [40] and in Danish HNSCC patients [41].
Satisfaction with the program
A semi-structured questionnaire was developed asking pa-
tients to grade the effect the program have had on their
physical, psychological, and social well-being on a scale
from 1 to 10, 1 being “very positively”; 10 being “very
negatively”. Furthermore, patients are asked if scheduling
was convenient and whether the PRT program was appro-
priate, too hard or too light (training group only). In
addition, they can make free text on all questions.
Work
Affiliation to work market will be registered as a measure
of convalescence, measuring how soon patients return to
work and to what extent. At 2, 6, and 12 months follow-
up patients fill in a questionnaire with information about
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current work status, date when work was resumed, and at
2 months follow-up, also, educational status, occupation,
and work hours prior to diagnosis will be registered.
Blinding procedures
Assessment of the primary endpoint (LBM) will be
blinded since the personnel performing DXA scans will
not be aware of randomization status of the patients.
Due to practicalities physical tests cannot be blinded.
However, tests are standardized and performed by the
same personnel regardless of randomization. Personnel
analyzing blood samples and muscle biopsies are blinded
to patient identity and group allocation.
Statistical considerations
The primary endpoint is difference in mean change of
LBM between the training and the control group, specif-
ically, whether attending this particular PRT program
can significantly attenuate the loss of LBM after 12 weeks
of PRT, which approximately aligns with the time where
the treatment is evaluated (2 months after end of radio-
therapy). Thus, the time at which the primary endpoint
is evaluated is at 12 weeks after initiation of PRT.
The second important decision was to define a clinically
meaningful endpoint in terms of difference in change in
LBM loss. Of course, the 12 week period in which it was
possible to train was included as a parameter since the
short training period would influence the possible out-
come, and even more so as patients were expected to lose
LBM as a result of side effects to treatment. Limited clin-
ical data were available on the possible effect of a 12-week
PRT program on LBM change during concomitant che-
moradiotherapy, though Lonbro et al. did find that head
and neck cancer patients attending a 12-week PRT pro-
gram initiated after radiotherapy gained an average of
2.3 kg (95% CI 1.7–3.0) [20]. A similar effect can probably
not be expected when PRT is performed during chemora-
diotherapy as the patients during this time are in a cata-
bolic state. This was seen in our pilot study where patients
despite PRT had a mean LBM loss of 3.6 kg (Lonkvist et
al., manuscript submitted).
Based on these deliberations we concluded that a dif-
ference of 25% in LBM loss between the exercise group
and the control group (which, estimated from data in
the pilot study, would be 1.2 kg of LBM in absolute dif-
ference) would be a clinically meaningful difference, and
yet, an obtainable goal in the circumstance of undergo-
ing CCRT.
Thus, the sample size calculation is based on changes
in LBM in our one-armed pilot study where a 3.6 kg re-
duction (corresponding to 6.8%) in LBM was detected
after 12 weeks of PRT (Lonkvist et al., manuscript sub-
mitted). A priori, a sample size of 34 in each group will
have 80% power to detect a difference in means of 25%
((9.06%–6.8%)/9.06%) between the two groups (corre-
sponding to an estimated mean LBM loss of 6.80% from
baseline in the training group and an estimated LBM
loss of 9.06% in the control group with a standard devi-
ation of 3.27). A two group t-test with a 0.05 two-sided
significance level was used.
An anticipated drop-out rate of 5% is included in the
calculations to ameliorate the risk of inadequate patient
number for analyses, hence 36 patients are planned to
be enrolled in each group (total n = 72). Patients drop-
ping out before or during the first week of treatment will
be replaced by another patient.
Analyses will include descriptive analyses as well as
mixed model repeated measures analyses examining dif-
ferences between groups and over time. The α-level of
statistical significance will be set to 0.05.
Discussion
An increasing body of evidence underlines the numerous
benefits of physical exercise in terms of improving pa-
tient wellbeing and rehabilitation after cancer therapy,
and very interestingly a tumor-inhibiting effect of exer-
cise is being unraveled [27, 42–47].
In particular head and neck cancer patients experience
perturbing loss of lean body mass and are severely af-
fected by treatment for weeks and months after comple-
tion [1, 48]. Thus, there is ample reason to investigate a
possible beneficial role of exercise during head and neck
cancer treatment but at the same time exercise studies
require careful attention to a number of issues. In par-
ticular, when investigating exercise in patients undergo-
ing CCRT a number of specific challenges must be
addressed. We designed a randomized trial on exercise
for head and neck cancer patients undergoing concomi-
tant CCRT and decided to describe the strategy in this
article about the protocol.
The choice of primary endpoint, as well as the assess-
ment hereof, should be cautiously chosen. We chose dif-
ference in change in LBM at the 12-week assessment, as
it has been shown that weight loss, especially loss of
LBM, may negatively affect physical function, morbidity
and mortality in patients undergoing CCRT [5, 7]. Thus,
it would be interesting to investigate if PRT may ameli-
orate LBM loss, and 12 weeks are often considered a
minimum amount of time for an effect on LBM by PRT.
Furthermore, a standard evaluation time point in head
and neck cancer patients is at this time as it almost coin-
cides with the 2-month post CCRT assessment. At this
time evaluation of the effect of treatment is performed
and side-effects have often diminished substantially.
The chosen assessment method is conventional DXA
scan based on several factors: Compared to other
methods it is a low risk, precise measurement of whole
body composition [49–52] where data may be retrieved
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and reevaluated at a later time point, if needed. Further-
more, it is fast and relatively inexpensive.
In this study we are only including patients receiving
an intense treatment with concomitant chemoradiother-
apy. The patients have the most intense treatment
schedule, hence, if it possible for them to attend and
benefit from the program, there is no reason to assume
that the findings may not be relevant for head and neck
cancer patients receiving other radiotherapy regimens.
Prescribing exercise in a training intervention study could
be thought of as prescribing medicine, where it is indisput-
able that specifications such as type, dose, interval, and dur-
ation of treatment are essential information in reporting. In
this trial, PRT is the obvious choice of training modality,
with the primary endpoint being change in LBM. Exercise
intensity, volume and frequency are chosen to ensure opti-
mal progression throughout the program and are based on
previous studies in HNSCC patients [20, 21] as well as
guidelines from the American College of Sports Medicine
(ACSM) [33]. Training days and number of sessions per
week are chosen to ensure adequate rest between sessions
for optimal hypertrophy response in the muscles. Likewise,
patients are instructed to exercise to exhaustion for max-
imal hypertrophic response. In general, all training sessions
are supervised by physiotherapists or educated training in-
structors. However, for practical reasons, an exception is
allowed, i.e. it will be possible for the last 6 weeks to train
at a public center closer to home, and only attend super-
vised training once a week to ensure progression. Unsuper-
vised training holds the advantage of flexibility for both
patient and caregiver team, while on the other hand, super-
vised sessions are a necessity to ensure that prescribed dose
is executed and reported correctly.
To ensure faster enrollment the study is conducted at
two institutions which can compromise standardization
of the PRT program. Three specific exercises differ, but
cautions are taken so that it should not influence pri-
mary outcome notably.
An essential aspect to consider is the fact that these
patients have a very busy schedule in regards to treat-
ment. Radiotherapy six times a week, combined with
chemotherapy treatment once a week, as well as ap-
pointments with doctors and nurses make planning a
challenge. Treatment delays are deleterious to outcome
[53], thus, planning training sessions, tests, and scans
conveniently so they do not interfere with treatment is
crucial. Furthermore, seeing to that patients do not have
too strenuous days and that meals are offered are also
significant factors for attendance and thus effect of the
intervention. The patients often suffer from side effects,
e.g. fatigue, nausea, and xerostomia, which are likely to
be limiting factors in any intention to exercise. Hence,
optimizing schedule is crucial for several reasons and
should be carefully managed.
Sufficient protein and energy supply is vital for muscle
growth or preservation. Hence, reporting on the effect of
any training modality in HNSCC patients must include
reporting of dietary intake, too. In this study customized
diet diaries are completed regularly by patients. These
diaries also form a basis for starting a conversation
about diet and advised strategy for the patient, e.g. about
tube feeding when necessary.
Anemia during radiotherapy is associated with response
to treatment [54–56] which is an important factor to con-
sider when planning blood sampling. Patients receive
weekly cisplatin, hence blood sampling is done weekly,
evaluating hematology. If hemoglobin is low blood sam-
pling for research purposes will be paused. Furthermore,
blood sampling for cytokine analyses are planned so that
only a maximum of 42 mL of extra blood is drawn during
the entire treatment period, while more frequent sampling
is done in the approximately 6 weeks after treatment.
Blood samples will be used for explorative analyses of
the differences between the groups in regards to cyto-
kines and cancer markers over time. Furthermore, the
PRT group will have samples taken before and after
training sessions to investigate whether a bout of resist-
ance training will release myokines and NK-cells as it is
known from endurance exercise [27, 57, 58]. Doing this
is important to contribute to the investigation of the bio-
logical mechanisms behind a possible effect. Muscle bi-
opsies are optional in order for it not to be a limiting
factor for patient recruitment. When performing sam-
ples on a part of patients, bias can be a concern, how-
ever, in our pilot study 2/3 of patients accepted muscle
biopsies (Lonkvist et al., manuscript submitted).
It is planned to investigate the effect of resistance train-
ing on changes in muscle fiber types, protein expression,
and metabolic pathways between the two groups.
Several patient-reported outcome measures are also eval-
uated in this study, including QoL and PA. Exercise has
been shown to increase QoL in cancer patients [59, 60],
and exercise studies in HNSCC patients confirm the posi-
tive effect [61–64]. Still, it is relevant to include QoL mea-
sures in new intervention studies, if the type of intervention
or program differs from prior programs. EORTC QLQ-30
and H&N-35 questionnaires have been chosen to evaluate
QoL, these questionnaires are validated and often used in
cancer research [2, 59]. PA is evaluated using the validated
PAS questionnaire [38] to assess level of PA in both groups
since an apparent bias is that patients in the control group
might start to exercise regularly, thereby affecting the be-
tween group differences.
To evaluate patients’ satisfaction with the program, we
developed a semi-structured questionnaire asking patients
about the effect of the program on their physical, psycho-
logical, and social well-being. We have added this to set a
direct reaction on what patients felt about the program.
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An inherent bias in all exercise trials is that patients
who have less comorbidity and are in better performance
status may be more inclined to accept participation. In
our pilot study all patients had p16-positive (HPV-asso-
ciated) tumors (Lonkvist et al., manuscript submitted).
Patients with p16-positive tumors have been shown to
have larger disease stages, averagely less tobacco and
alcohol consumption, fewer comorbidities, and be in
better performance status [65]. Further studies will be
needed to look at the effects of exercise programs in pa-
tients with poor performance status, comorbidities, or
with a history of tobacco or alcohol consumption.
Designing and performing exercise trials in cancer pa-
tients requires careful consideration to optimal modality,
dose, duration, and many other parameters depending on
desired outcome measures. Also, and at least as important,
is a detailed description in order to ensure clarity and re-
producibility. Finally, interpretation of biological sampling
for mechanistic investigations must be recommended and
these samples, in connection with the clinical data, may
help to generate important knowledge. With this study, we
hope to contribute with influential results regarding pro-
gressive resistance training in head and neck cancer pa-
tients undergoing concomitant chemoradiotherapy.
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